Montreal, QC, Aug. 08, 2026 (GLOBE NEWSWIRE) — Tyros Biopharma, a privately held Canadian pharmaceutical company focused on women’s health, is pleased to announce its continued growth following the addition of four new products to its portfolio in 2026: Gynatrof MenoControl, Uriexo Control+, Uriexo Attack+ and Uriexo CystiRelief+. Additional products are currently in development as Tyros Biopharma continues to broaden its offerings and respond to evolving women’s health needs.